Trial | NCT04898088  Report issue

Official Title

A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    30
Our aim in this study is to determine the positive effect of stem cell therapy applied on critically ill patients with coronavirus infection on DNA repair genes.

Patients diagnosed with COVID-19 infection are divided into two equal (n:30) groups. Group-1(n/15): Patients in critically ill condition receiving conventional therapy, Group-2 (n/15): Patients in critically ill condition receiving conventional therapy and systemically transplanted MSCs. The DNA repair pathway will be examined as 11 genes in 5 different parts. Investigated parameters:

Base excision repair
Nucleotide excision repair
Recombinational repair
Mismatch repair
Direct reversal Investigated parameters: broad biochemical analysis, apoptosis, clinical outcome, and mortality rates.
Our aim in this study is to determine the positive effect of stem cell therapy applied on critically ill patients with coronavirus infection on DNA repair genes.

Patients diagnosed with COVID-19 infection are divided into two equal (n:30) groups. Group-1(n/15): Patients in critically ill condition receiving conventional therapy, Group-2 (n/15): Patients in critically ill condition receiving conventional therapy and systemically transplanted MSCs. The DNA repair pathway will be examined as 11 genes in 5 different parts. Investigated parameters:

Base excision repair
Nucleotide excision repair
Recombinational repair
Mismatch repair
Direct reversal Investigated parameters: broad biochemical analysis, apoptosis, clinical outcome, and mortality rates.
Study Started
Jan 01
2020
Primary Completion
Aug 30
2020
Study Completion
Sep 30
2020
Last Update
May 24
2021

Biological Mesenchymal Stem Cells Transplantation

Mesenchymal Stem Cells Transplantation applied as three intravenous infusions with 30 days intervals

Conventional Therapy Experimental

Conventional Therapy with Add-On MSC therapy Experimental

Criteria 

Inclusion Criteria:

40-65 years old male/female.
Obtaining informed consent from him or his legal relative.
Confirmed COVID-19 related severe ARDS cases.

Exclusion Criteria:

pregnant, malignant tumours, the ones who has confirmed co-infection; history of using long-term immunosuppressive agents
No Results Posted